CA3095373A1 - Nk cell engaging antibody fusion constructs - Google Patents
Nk cell engaging antibody fusion constructs Download PDFInfo
- Publication number
- CA3095373A1 CA3095373A1 CA3095373A CA3095373A CA3095373A1 CA 3095373 A1 CA3095373 A1 CA 3095373A1 CA 3095373 A CA3095373 A CA 3095373A CA 3095373 A CA3095373 A CA 3095373A CA 3095373 A1 CA3095373 A1 CA 3095373A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18167385 | 2018-04-13 | ||
| EP18167385.6 | 2018-04-13 | ||
| EP18167384 | 2018-04-13 | ||
| EP18167384.9 | 2018-04-13 | ||
| EP18190662 | 2018-08-24 | ||
| EP18190662.9 | 2018-08-24 | ||
| EP18190661 | 2018-08-24 | ||
| EP18190661.1 | 2018-08-24 | ||
| PCT/IB2019/053040 WO2019198051A2 (en) | 2018-04-13 | 2019-04-12 | Nk cell engaging antibody fusion constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3095373A1 true CA3095373A1 (en) | 2019-10-17 |
Family
ID=66625219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3095373A Pending CA3095373A1 (en) | 2018-04-13 | 2019-04-12 | Nk cell engaging antibody fusion constructs |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11001633B2 (enExample) |
| EP (1) | EP3774914A2 (enExample) |
| JP (2) | JP2021521275A (enExample) |
| KR (1) | KR20200143436A (enExample) |
| CN (3) | CN113817066A (enExample) |
| AU (2) | AU2019252970A1 (enExample) |
| BR (1) | BR112020020828A2 (enExample) |
| CA (1) | CA3095373A1 (enExample) |
| CL (2) | CL2020002625A1 (enExample) |
| CO (1) | CO2020014167A2 (enExample) |
| CR (1) | CR20200549A (enExample) |
| IL (1) | IL277925A (enExample) |
| MA (1) | MA52227A (enExample) |
| MX (1) | MX2020010728A (enExample) |
| PE (1) | PE20201346A1 (enExample) |
| PH (1) | PH12020551664B1 (enExample) |
| RU (1) | RU2022105827A (enExample) |
| SG (1) | SG11202010064QA (enExample) |
| TW (1) | TW202012441A (enExample) |
| WO (1) | WO2019198051A2 (enExample) |
| ZA (1) | ZA202006325B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220396635A1 (en) * | 2019-09-25 | 2022-12-15 | Universität Stuttgart | Trivalent binding molecules |
| US20230227559A1 (en) * | 2019-12-10 | 2023-07-20 | Institut Pasteur | New antibody blocking human fcgriiia and fcgriiib |
| GB201919058D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| AU2020414409A1 (en) | 2019-12-27 | 2022-06-16 | Affimed Gmbh | Method for the production of bispecific FcyRIIl x CD30 antibody construct |
| WO2022002033A1 (zh) * | 2020-06-30 | 2022-01-06 | 和铂医药(上海)有限责任公司 | 具有H2L2与HCAb结构的结合蛋白 |
| CN116368154A (zh) | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| JP2023548538A (ja) * | 2020-11-08 | 2023-11-17 | シージェン インコーポレイテッド | 併用療法 |
| WO2022120033A1 (en) * | 2020-12-03 | 2022-06-09 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
| CA3209579A1 (en) * | 2021-01-27 | 2022-08-04 | Innovent Biologics (Suzhou) Co., Ltd. | Single-domain antibody against cd16a and use thereof |
| WO2022232503A1 (en) | 2021-04-30 | 2022-11-03 | Genentech, Inc. | Therapeutic and diagnostic methods and compositions for cancer |
| AU2022320948A1 (en) | 2021-07-30 | 2024-01-18 | Affimed Gmbh | Duplexbodies |
| WO2023006082A1 (zh) * | 2021-07-30 | 2023-02-02 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| CN113929785B (zh) * | 2021-09-10 | 2023-05-23 | 钦元再生医学(珠海)有限公司 | 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用 |
| AU2022353119A1 (en) * | 2021-09-24 | 2024-04-11 | Synergy Imt, Inc. | Composition of recombinant antigen binding molecules and method of making and using thereof |
| AU2022381918A1 (en) | 2021-11-03 | 2024-06-13 | Affimed Gmbh | Bispecific cd16a binders |
| JP2024543822A (ja) | 2021-11-03 | 2024-11-26 | アフィメド ゲーエムベーハー | 二重特異性ｃｄ１６ａバインダー |
| CN116284385A (zh) * | 2021-12-07 | 2023-06-23 | 信达细胞制药(苏州)有限公司 | 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用 |
| CN114349869B (zh) * | 2021-12-20 | 2023-09-26 | 上海恩凯细胞技术有限公司 | 一种双特异性的nk细胞激动剂及制备方法和应用 |
| JP2025528087A (ja) * | 2022-08-05 | 2025-08-26 | チマゲン・バイオサイエンシズ，リミテッド | 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体 |
| CA3267339A1 (en) * | 2022-09-14 | 2024-03-21 | Otsuka Pharmaceutical Co., Ltd. | PD-1 AGONIST ANTIBODIES |
| CN120641128A (zh) * | 2023-02-06 | 2025-09-12 | 乐普创一生物科技（上海）有限公司 | 抗cd16a抗体及其用途 |
| WO2024186092A1 (ko) * | 2023-03-06 | 2024-09-12 | 주식회사 드노보 바이오테라퓨틱스 | 신규한 항-cd16 항체 및 이의 용도 |
| WO2025257588A1 (en) * | 2024-06-10 | 2025-12-18 | Affimed Gmbh | Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance |
| WO2026087751A1 (en) | 2024-10-24 | 2026-04-30 | Affimed Gmbh | Combination of immune cell engager and nk cell products |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2438682A1 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| KR101589785B1 (ko) | 2009-03-10 | 2016-01-28 | 바이오젠 엠에이 인코포레이티드 | 항-ｂｃｍａ 항체 |
| LT2361936T (lt) * | 2010-02-25 | 2016-09-12 | Affimed Gmbh | Antigeną rišanti molekulė ir jos panaudojimas |
| SI3415531T1 (sl) | 2011-05-27 | 2023-12-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - vezni proteini |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| US9676857B2 (en) | 2012-03-16 | 2017-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble engineered monomeric Fc |
| US11180572B2 (en) * | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
| ES2937015T3 (es) | 2012-11-01 | 2023-03-23 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Anticuerpo contra CD269 (BCMA) |
| US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| WO2014144357A1 (en) * | 2013-03-15 | 2014-09-18 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| US20160326249A1 (en) * | 2014-01-15 | 2016-11-10 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| DK3237005T3 (en) * | 2014-12-22 | 2024-11-18 | Systimmune Inc | Bispecific tetravalent antibodies and methods of making and using thereof |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| EP3091031A1 (en) * | 2015-05-04 | 2016-11-09 | Affimed GmbH | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor |
| PT3292153T (pt) * | 2015-05-04 | 2019-11-05 | Affimed Gmbh | Combinação de um anticorpo cd30xcd16a com um anticorpo antagonístico anti-pd-1 para terapia |
| WO2016207278A1 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
| WO2017031104A1 (en) * | 2015-08-17 | 2017-02-23 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| CA3051062C (en) * | 2017-02-28 | 2023-09-26 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
-
2019
- 2019-04-12 EP EP19725409.7A patent/EP3774914A2/en active Pending
- 2019-04-12 BR BR112020020828-0A patent/BR112020020828A2/pt unknown
- 2019-04-12 PH PH1/2020/551664A patent/PH12020551664B1/en unknown
- 2019-04-12 AU AU2019252970A patent/AU2019252970A1/en not_active Abandoned
- 2019-04-12 CN CN202111125475.XA patent/CN113817066A/zh active Pending
- 2019-04-12 WO PCT/IB2019/053040 patent/WO2019198051A2/en not_active Ceased
- 2019-04-12 CA CA3095373A patent/CA3095373A1/en active Pending
- 2019-04-12 MX MX2020010728A patent/MX2020010728A/es unknown
- 2019-04-12 SG SG11202010064QA patent/SG11202010064QA/en unknown
- 2019-04-12 PE PE2020001584A patent/PE20201346A1/es unknown
- 2019-04-12 CR CR20200549A patent/CR20200549A/es unknown
- 2019-04-12 CN CN202111125559.3A patent/CN113880952A/zh active Pending
- 2019-04-12 JP JP2021504593A patent/JP2021521275A/ja active Pending
- 2019-04-12 KR KR1020207032435A patent/KR20200143436A/ko not_active Ceased
- 2019-04-12 RU RU2022105827A patent/RU2022105827A/ru unknown
- 2019-04-12 CN CN201980033176.8A patent/CN112119097B/zh active Active
- 2019-04-12 MA MA052227A patent/MA52227A/fr unknown
- 2019-04-15 TW TW108113068A patent/TW202012441A/zh unknown
- 2019-12-13 US US16/714,396 patent/US11001633B2/en active Active
-
2020
- 2020-10-09 CL CL2020002625A patent/CL2020002625A1/es unknown
- 2020-10-11 IL IL277925A patent/IL277925A/en unknown
- 2020-10-12 ZA ZA2020/06325A patent/ZA202006325B/en unknown
- 2020-11-12 CO CONC2020/0014167A patent/CO2020014167A2/es unknown
-
2021
- 2021-04-20 US US17/235,854 patent/US20210253698A1/en not_active Abandoned
-
2023
- 2023-04-14 CL CL2023001085A patent/CL2023001085A1/es unknown
-
2024
- 2024-04-17 US US18/637,556 patent/US20240294647A1/en active Pending
-
2025
- 2025-01-17 JP JP2025006634A patent/JP2025081307A/ja active Pending
-
2026
- 2026-01-27 AU AU2026200541A patent/AU2026200541A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11001633B2 (en) | 2021-05-11 |
| JP2021521275A (ja) | 2021-08-26 |
| AU2019252970A1 (en) | 2020-11-26 |
| CN112119097A (zh) | 2020-12-22 |
| CN113880952A (zh) | 2022-01-04 |
| IL277925A (en) | 2020-11-30 |
| TW202012441A (zh) | 2020-04-01 |
| CO2020014167A2 (es) | 2021-04-08 |
| SG11202010064QA (en) | 2020-11-27 |
| US20200109202A1 (en) | 2020-04-09 |
| PE20201346A1 (es) | 2020-11-25 |
| ZA202006325B (en) | 2025-12-17 |
| CN112119097B (zh) | 2021-10-15 |
| AU2026200541A1 (en) | 2026-02-19 |
| PH12020551664B1 (en) | 2023-05-19 |
| WO2019198051A2 (en) | 2019-10-17 |
| MX2020010728A (es) | 2020-11-06 |
| WO2019198051A3 (en) | 2019-11-14 |
| JP2025081307A (ja) | 2025-05-27 |
| MA52227A (fr) | 2021-04-21 |
| BR112020020828A2 (pt) | 2021-01-19 |
| CN113817066A (zh) | 2021-12-21 |
| PH12020551664A1 (en) | 2021-12-13 |
| RU2022105827A (ru) | 2022-04-05 |
| US20210253698A1 (en) | 2021-08-19 |
| US20240294647A1 (en) | 2024-09-05 |
| KR20200143436A (ko) | 2020-12-23 |
| EP3774914A2 (en) | 2021-02-17 |
| CR20200549A (es) | 2021-03-18 |
| CL2023001085A1 (es) | 2023-10-06 |
| CL2020002625A1 (es) | 2021-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240294647A1 (en) | Uses of nk cell engaging antibody fusion constructs for treatments | |
| JP7853939B2 (ja) | 二重特異性チェックポイント阻害剤抗体 | |
| JP7773528B2 (ja) | 抗ｃｄ２８組成物 | |
| US11377477B2 (en) | PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof | |
| AU2018228719B2 (en) | Tandem diabody for CD16A-directed NK-cell engagement | |
| CN110214148A (zh) | 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白 | |
| CN119365490A (zh) | 结合pd-l1、pd-l2和/或cd28的抗体 | |
| RU2774711C2 (ru) | Слитые конструкции антител для вовлечения nk-клеток | |
| HK40066389A (zh) | 自然杀伤细胞接合抗体融合构建体 | |
| HK40066055A (zh) | 自然杀伤细胞接合抗体融合构建体 | |
| HK40034204A (en) | Nk cell engaging antibody fusion constructs | |
| HK40034204B (en) | Nk cell engaging antibody fusion constructs | |
| HK40016394B (zh) | 双特异性检查点抑制剂抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240412 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20240718 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250131 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250227 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250228 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250325 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250325 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250401 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250924 |